Joanne M. Donovan, Chief Medical Officer at Edgewise Therapeutics (NASDAQ: EWTX), completed a set of related equity transactions on April 1, 2026 that included both a sale of shares and the exercise of stock options.
According to a Form 4 filing with the Securities and Exchange Commission, Donovan sold 28,662 shares of common stock for approximately $926,095. The trades were executed at an average price of $32.3109, with individual executions in a price band between $32.00 and $32.60. The filing notes the sale occurred under a pre-arranged Rule 10b5-1 trading plan that was adopted on December 26, 2025.
On the same day Donovan exercised options to acquire 28,662 shares of Edgewise common stock at an exercise price of $7.08, for a total exercise cost of $202,926. After these transactions Donovan is recorded as directly owning 9,597 shares of the company.
Market context around the transaction highlights that EWTX is trading close to its 52-week high of $33.47. The stock has experienced a strong run over the past year, rising more than 113% from a 52-week low of $10.60. InvestingPro analysis included in public reporting indicates the stock currently appears overvalued relative to its Fair Value, with the company carrying a market capitalization of $3.52 billion.
Investors seeking further detail on Edgewise’s valuation and financial profile are pointed to the comprehensive Pro Research Report, which is available for EWTX and more than 1,400 other U.S. equities on InvestingPro.
Alongside the insider transactions, Edgewise has been subject to several analyst updates tied to recent clinical data. The company reported results from the MESA open-label extension study showing that participants with Becker muscular dystrophy treated with sevasemten maintained stable function over a 3.5-year period. This long-term data was presented at the 2026 MDA Clinical and Scientific Conference.
Following the presentation, Raymond James reiterated a Strong Buy rating for Edgewise and maintained a $46 price target, citing the positive long-term trial data. Truist Securities also reiterated a Buy rating and a $46 price target after observing stabilization of function among trial participants.
In addition, several firms adjusted price targets upward while keeping constructive ratings. JPMorgan raised its price target to $45 from $34 and maintained an Overweight rating, citing anticipated catalysts in the company’s pipeline, particularly around EDG-7500. Evercore ISI similarly increased its price target to $45 from $30 and kept an Outperform rating, highlighting expectations for upcoming EDG-7500 data in the first half of 2026. These analyst actions reflect continued optimism tied to the company’s clinical agenda and expected near-term data milestones.
Note: The transactions described above are taken from the Form 4 filing and publicly reported analyst commentary. The article reflects those records and the market context presented therein.